CMS Open Payments · Program Year 2024
F. Hoffmann-La Roche AG
F. Hoffmann-La Roche AG reported $25,776,647.33 across General Payments, Research, and Ownership to 1,104 physicians and teaching hospitals across 6,185 transactions.
- $25.8M
- All-tracks total
- 6,185
- Transactions
- 1,104
- Recipients
- −$395.7K
- General Payments vs PY2023
F. Hoffmann-La Roche AG reported $25,776,647.33 across all CMS Open Payments tracks (General + Research + Ownership) to 1,104 physicians and teaching hospitals in Program Year 2024 - ranking #80 of 1,925 reporting manufacturers (0.2% of the all-tracks industry total); General Payments alone were $2,522,602.16, averaging $23.3K per recipient.
Data currency: Figures are rendered from the processed CMS Open Payments release. See our methodology for source dates and refresh cadence. Spot a figure that looks wrong? Report a correction.
CMS Sunshine Act warrant
Manufacturer f-hoffmann-la-roche-ag F. Hoffmann-La Roche AG
$25.8M · #80/1,925 · 0.2% industry · PY2024
- TOT $25.8M
- RANK #80
- SHARE 0.2%
- TXN 6,185
- RCP 1,104
- CAT 5
- GEN $2.5M
- ΔGEN −$395.7K
- TOP1 11.9%
- PY 2024
Volume peers
Nearest volume peer: LivaNova USA, Inc. ($26.3M)
F. Hoffmann-La Roche AG sits among 1,925 manufacturers disclosing under the Physician Payments Sunshine Act. Volume peers below are nearest by all-tracks total, not corporate affiliates. Open the company rankings →
Release-over-release change
General Payments changed from PY2023 to PY2024
F. Hoffmann-La Roche AG's CMS-reported General Payments decreased by $395.7K (−13.6%) from PY2023 to PY2024.
How this year-over-year comparison is scoped
The comparison uses consecutive CMS program years only (current = prior + 1) from the manufacturer General Payments summary and excludes research and ownership or investment records. Non-consecutive year pairs are not shown as year-over-year change. This General Payments figure is not the all-tracks company total in the hero.
CMS source labels for this exact identifier: PY2022: F. HOFFMANN-LA ROCHE AGPY2023: F. HOFFMANN-LA ROCHE AGPY2024: F. Hoffmann-La Roche AG. Matching identifiers support a bounded record comparison; a label difference would be reported as unresolved rather than treated as a corporate event.
Subscribe to this company's source-bounded update feed It publishes only identifier-matched CMS release comparisons, never inferred company events.
General Payments: PY2023 vs PY2024
Annual CMS-reported totals for this company, not an all-category Open Payments total
- PY2023
- $2,918,288.30
- PY2024
- $2,522,602.16
What the Data Shows for F. Hoffmann-La Roche AG
F. Hoffmann-La Roche AG ranks #80 out of 1,925 companies in the CMS Open Payments database for Program Year 2024, representing 0.2% of all industry payments reported nationwide for the year. The underlying total is $25,776,647.33 across 6,185 transactions to 1,104 physicians and teaching hospitals - $4.2K per transaction and $23.3K per recipient on average.
The 5-category breakdown below covers general payments only (see our methodology for how research and ownership payments are reported separately). The largest general-payment category is "Consulting Fee" at $1.3M, accounting for 50.5% of this company's General Payments and 477 transactions.
General Payment Breakdown by Type
F. Hoffmann-La Roche AG made 5 types of general payments. "Consulting Fee" is the largest category at $1.3M, 50.5% of General Payments.
F. Hoffmann-La Roche AG reports 5 general-payment categories - the top three are Consulting Fee (50.5%), Travel and Lodging (34.2%), and Royalty or License (13.5%). The remaining 2 categories make up 1.8% of this company's reported general-payment total. That multi-category mix is the kind of profile single-category reporters cannot show.
How F. Hoffmann-La Roche AG divides its payments
Top payment categories by total reported dollar volume
| Payment Type | Amount | Transactions | % of Total |
|---|---|---|---|
| Consulting Fee | $1.3M | 477 | 50.5% |
| Travel and Lodging | $863.1K | 356 | 34.2% |
| Royalty or License | $340.0K | 4 | 13.5% |
| Food and Beverage | $36.6K | 256 | 1.5% |
| Compensation for Services Other Than Consulting | $9.8K | 11 | 0.4% |
Recipient Concentration in General Payments
The five largest recipient relationships account for $497,722.06 (19.7%) of $2,522,602.16 in this company's General Payments records across 336 recipients.
General Payments scope note
Program Year 2024 General Payments view only: excludes research and ownership/investment records, so it is not the all-category company total above.
Largest General-Payment relationships for F. Hoffmann-La Roche AG
The five named recipients with the highest reported General Payments from this company
- 1
Ut Md Anderson Cancer Center
$300,000.00 across 1 reported transactions
- 2
Arshad Khanani
$80,674.94 across 25 reported transactions
- 3
Veeral Sheth
$42,865.01 across 20 reported transactions
- 4
Srinivas Sadda
$37,941.88 across 17 reported transactions
- 5
Richard Finn
$36,240.23 across 12 reported transactions
Compare this company's payment profile with similarly sized manufacturers in the company comparison tool, and consult the methodology for the CMS source scope.
Similarly Concentrated Companies
Companies whose General Payments are spread across recipients about as (un)evenly as F. Hoffmann-La Roche AG's, measured by the same HHI concentration index above, not by payment size.
What HHI 2,500 means here
2,500 is the DOJ/FTC merger-guidelines threshold for "highly concentrated" markets; used here only as a familiar concentration reference, not a legal finding about F. Hoffmann-La Roche AG.
Companies with Similar Payment Volumes
Open a profile or compare a similar company's CMS-reported payment pattern with F. Hoffmann-La Roche AG.
Showing 6 of 1,924 companies with CMS-reported payment data.
United Therapeutics Corporation
Cardio Flow, Inc.
Regeneron Healthcare Solutions, Inc.
Henry Schein, Inc.
Grace Medical, Inc.
Disclaimer
This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the CMS Open Payments program. Consult a qualified professional before making decisions based on this data.
Read our methodology - how this data is sourced, computed, and verified.
Every figure on PlainPharmaWatch is rendered directly from federal source data, no number is typed in by an editor. This page draws directly on federal source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of 2026-07-26.